Outcome study on parenterally administered shenfu in treatment of coronary heart disease.
- Author:
Jing YANG
1
;
Lin LI
2
;
Yan-Ming XIE
3
;
Hao SHEN
3
;
Yan ZHUANG
4
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Aged; Aged, 80 and over; Aspirin; therapeutic use; Coronary Disease; drug therapy; Drug Therapy, Combination; Drugs, Chinese Herbal; administration & dosage; adverse effects; Female; Hospital Information Systems; statistics & numerical data; Humans; Infusions, Parenteral; Isosorbide Dinitrate; therapeutic use; Male; Middle Aged; Outcome Assessment (Health Care); Pragmatic Clinical Trials as Topic
- From: China Journal of Chinese Materia Medica 2013;38(18):3099-3103
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo understand the clinical circumstances for the use of parenterally administered Shenfu in the treatment of coronary heart disease, in order to provide a reference guide for its clinical use.
METHODInformation was extracted and summarized on the treatment of coronary heart disease patients, who received parenterally administered Shenfu, from 20 nationwide general hospitals HIS data. Descriptive statistical methods were used to analyze the usage and dosage. Correlation analysis was adopted to analyze information including drug combinations, and outcomes were compared with other combinations.
RESULTReal world HIS data showed that the drug delivery method for parenterally administered Shenfu was intravenous infusion. Treatment courses were from 3 to7 days, at a dosage of 60 mL. The drug combination was mostly with chemical drugs. The most common combinations were Shenfu plus clopidogrel, aspirin and isosorbide dinitrate.
CONCLUSIONParenterally administered Shenfu is a common drug used in the treatment of coronary heart disease. Most of the usage was in accordance with instructions. The chemical combination drugs were mainly clopidogrel, aspirin and isosorbide dinitrate.
